drugset / Trial / NCT03086369
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
Timeline
- Start
- 2017-06-22
- Primary completion
- 2021-01-05
- Completion
- 2021-06-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaratumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Olaratumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |